Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to flumatinib in CML patients after suboptimal or intolerant first-/second-line TKI therapy
ChiCTR2000040558Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Flumatinib in chronic myelogenous leukemia (CML), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Major Molecular Response. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
Flumatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2000040558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040558.